Coya Therapeutics Ownership | Who Owns Coya Therapeutics?
Coya Therapeutics Ownership Summary
Coya Therapeutics is owned by 27.89% institutional investors, 7.02% insiders, and 65.10% retail investors.
COYA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Coya Therapeutics | 27.89% | 7.02% | 65.10% |
| Sector | Healthcare Stocks | 279.20% | 10.62% | -189.82% |
| Industry | Biotech Stocks | 63.97% | 10.74% | 25.29% |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 26 | - | 4,662,591 | 4.94% | 27 | 3.28% | 16 | -15.79% | 4 | - |
| Dec 31, 2024 | 26 | 36.84% | 4,443,112 | 34.02% | 29 | 6.15% | 19 | 216.67% | 4 | -33.33% |
| Sep 30, 2024 | 19 | - | 3,315,161 | 1.43% | 21 | 4.54% | 6 | -33.33% | 6 | - |
| Jun 30, 2024 | 19 | - | 3,268,292 | -2.12% | 21 | 4.11% | 9 | -30.77% | 6 | 100.00% |
| Mar 31, 2024 | 19 | -9.52% | 3,339,071 | 18.31% | 23 | 3.00% | 13 | -13.33% | 3 | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Nov 14, 2024 | SNYDER DAVID S | Chief Financial Officer | Buy | $12.93K |
| Nov 13, 2024 | Swaminathan Arun | Chief Executive Officer | Buy | $36.80K |
| Nov 11, 2024 | Grossman Fred | Chief Medical Officer | Buy | $19.97K |
| Nov 11, 2024 | Swaminathan Arun | Chief Executive Officer | Buy | $36.69K |
| Aug 22, 2023 | Lee Ann | - | Buy | $3.62K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | - | - |
| 2024 Q4 | 4 | - |
| 2024 Q3 | - | - |
| 2024 Q2 | - | - |
| 2024 Q1 | - | - |
COYA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools